Extracellular vesicles from second trimester human amniotic fluid as candidate therapeutics against myocardial injury
Laura Guerricchio, G Senesi, V Zazza, G Damonte et autres
Abstract Background We have previously reported that human amniotic fluid (hAF) from II trimester of gestation is an appealing source of stromal progenitor cells (hAFSCs) that release in their secretome extracellular vesicles (EVs) with pro-survival, proliferative, anti-fibrotic effects in preclinical skeletal and …
it, ch, by, us (code pays fourni par la source)
0 citations
European Heart Journal